CONTACTAbout UsCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2025 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
In a major setback in the development of HIV fusion inhibitors, Roche and Trimeris announced Monday that they have halted development of their experimental drug T-1249, a highly touted second-generation version of their already approved medication Fuzeon. Clinical development of the compound was put on indefinite hold due to challenges in manufacturing the complex medication, according to company officials. The current batch of T-1249 available is not suitable for use in advanced clinical trials, they added. However, basic research into a formulation of T-1249 that is easier to mass produce will continue at the pharmaceutical companies. AIDS experts had viewed T-1249 as the leading fusion inhibitor candidate in development based on previous reports that the compound was more effective than Fuzeon, the only approved fusion inhibitor, in preventing HIV from attaching to and infecting immune system cells. Company officials say the compound is effective but just too difficult to manufacture. "T-1249's safety, efficacy, and tolerability profile as determined to date in Phase I trials were not the reasons for this decision," Miklos Salgo, director of Roche Virology, Clinical Science, wrote to T-1249 and Fuzeon investigators. "The challenges we have encountered with T-1249 are not shared by Fuzeon. Thus, this action has no impact whatsoever on Fuzeon or on the continued use of Fuzeon by patients." Company officials say that despite halting development of the drug, Roche and Trimeris will manufacture enough of the medication to provide it free to all patients currently enrolled in a human trial of the medication through the study's 96-week endpoint. The companies also plan to continue to develop other fusion inhibitor candidates and announced the signing of a three-year extension of a research agreement to "work together to discover new HIV fusion inhibitors and to pursue improved formulations and delivery technologies which may be applicable to Fuzeon, T-1249, and future peptide fusion inhibitors."
From our Sponsors
Most Popular
31 Period Films of Lesbians and Bi Women in Love That Will Take You Back
December 09 2024 1:00 PM
18 of the most batsh*t things N.C. Republican governor candidate Mark Robinson has said
October 30 2024 11:06 AM
True
After 20 years, and after tonight, Obama will no longer be the Democrats' top star
August 20 2024 12:28 PM
Trump ally Laura Loomer goes after Lindsey Graham: ‘We all know you’re gay’
September 13 2024 2:28 PM
These 15 major companies caved to the far right and stopped DEI programs
January 24 2025 1:11 PM
True
Latest Stories
Immigration's public image crisis is fueled by Trump and right-wing extremists
February 11 2025 7:10 PM
Pete Hegseth receives jeers from U.S. service members’ families at military base in Germany
February 11 2025 5:12 PM
Booz Allen Hamilton drops sponsorship of WorldPride, cites Donald Trump's anti-DEI order
February 11 2025 4:29 PM
Dad's heartwarming reaction to his son coming out as gay goes viral 8 years later
February 11 2025 12:55 PM
Trump taps gay MAGA loyalist Ric Grenell as interim head of Kennedy Center
February 11 2025 11:52 AM
Google Calendar removes Pride Month and Black History Month shortly after dropping DEI
February 11 2025 11:20 AM
Trump Pentagon chief Pete Hegseth enacts harshest anti-trans military policies yet
February 11 2025 9:57 AM